Percutaneous microwave ablation of bone lesions: a retrospective cohort study.

IF 4.5 2区医学 Q1 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING

Insights into Imaging Pub Date : 2025-09-17 DOI:10.1186/s13244-025-02083-6

Sylvain Bodard, Amgad M Moussa, Max Vaynrub, Meredith Bartelstein, Ernesto Santos-Martin, Majid Maybody, Francois H Cornelis

{"title":"Percutaneous microwave ablation of bone lesions: a retrospective cohort study.","authors":"Sylvain Bodard, Amgad M Moussa, Max Vaynrub, Meredith Bartelstein, Ernesto Santos-Martin, Majid Maybody, Francois H Cornelis","doi":"10.1186/s13244-025-02083-6","DOIUrl":null,"url":null,"abstract":"Purpose: To evaluate the feasibility, safety, and efficacy of microwave ablation (MWA) of bone lesions with regard to local control and pain palliation.Materials and methods: We reviewed 43 patients (23 males, 20 females) with 51 lesions (44 metastatic, 7 benign) treated with MWA from January 2016 to December 2023. Pain intensity was measured using the Visual Analogue Scale (VAS), SF-36 Bodily Pain Scale, and Patient Global Impression of Change (PGIC) from pre-operation to various follow-up stages. Adverse events were categorized according to the Society of Interventional Radiology (SIR) grading system.Results: The procedure demonstrated 100% technical success. Grades I and III adverse events were observed in 8.3% (3/36) and 2.8% (1/36) of patients with metastatic disease, respectively. In those with benign lesions, no adverse events were reported. A significant reduction in pain was observed, with the VAS score decreasing by 74.3% from baseline to the last follow-up [6.7 ± 2.3 (range: 0-10) to 1.8 ± 2.3 (range: 0-7) (p < 0.001)] for metastatic patients, and from 5.7 ± 2.1 (range: 3-8) to 0 ± 0 (range: 0-0) by the final follow-up (p = 0.0011) for benign lesions. 77.8% (29/36) of metastatic patients, and all (7/7) benign patients were much or very much improved according to Patient Global Impression Change. Complete imaging response was achieved in 55.6% (20/36) of metastatic lesions. At last follow-up, 25% (9/36) had radiological evidence of recurrence, with a median recurrence time of 13 months (IQR: 8-14). Complete response was achieved in all benign lesions.Conclusions: MWA is a safe and effective treatment for pain management in patients with bone lesions.Critical relevance statement: This study confirms the potential of microwave ablation as a treatment for bone lesions, providing significant pain relief with a favorable safety profile.Key points: Microwave ablation (MWA) significantly reduced pain scores in patients with bone lesions, maintaining pain relief over time. The procedure exhibited high technical success with minimal adverse events, indicating a high safety profile. Subgroup analysis revealed no significant differences in pain reduction among different procedural combinations over time.","PeriodicalId":13639,"journal":{"name":"Insights into Imaging","volume":"16 1","pages":"193"},"PeriodicalIF":4.5000,"publicationDate":"2025-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12443645/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Insights into Imaging","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s13244-025-02083-6","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: To evaluate the feasibility, safety, and efficacy of microwave ablation (MWA) of bone lesions with regard to local control and pain palliation.

Materials and methods: We reviewed 43 patients (23 males, 20 females) with 51 lesions (44 metastatic, 7 benign) treated with MWA from January 2016 to December 2023. Pain intensity was measured using the Visual Analogue Scale (VAS), SF-36 Bodily Pain Scale, and Patient Global Impression of Change (PGIC) from pre-operation to various follow-up stages. Adverse events were categorized according to the Society of Interventional Radiology (SIR) grading system.

Results: The procedure demonstrated 100% technical success. Grades I and III adverse events were observed in 8.3% (3/36) and 2.8% (1/36) of patients with metastatic disease, respectively. In those with benign lesions, no adverse events were reported. A significant reduction in pain was observed, with the VAS score decreasing by 74.3% from baseline to the last follow-up [6.7 ± 2.3 (range: 0-10) to 1.8 ± 2.3 (range: 0-7) (p < 0.001)] for metastatic patients, and from 5.7 ± 2.1 (range: 3-8) to 0 ± 0 (range: 0-0) by the final follow-up (p = 0.0011) for benign lesions. 77.8% (29/36) of metastatic patients, and all (7/7) benign patients were much or very much improved according to Patient Global Impression Change. Complete imaging response was achieved in 55.6% (20/36) of metastatic lesions. At last follow-up, 25% (9/36) had radiological evidence of recurrence, with a median recurrence time of 13 months (IQR: 8-14). Complete response was achieved in all benign lesions.

Conclusions: MWA is a safe and effective treatment for pain management in patients with bone lesions.

Critical relevance statement: This study confirms the potential of microwave ablation as a treatment for bone lesions, providing significant pain relief with a favorable safety profile.

Key points: Microwave ablation (MWA) significantly reduced pain scores in patients with bone lesions, maintaining pain relief over time. The procedure exhibited high technical success with minimal adverse events, indicating a high safety profile. Subgroup analysis revealed no significant differences in pain reduction among different procedural combinations over time.

Abstract Image

查看原文本刊更多论文

经皮微波消融骨病变：一项回顾性队列研究。

目的：评价微波消融（MWA）治疗骨病变在局部控制和疼痛缓解方面的可行性、安全性和有效性。材料和方法：我们回顾了2016年1月至2023年12月期间，43例（男性23例，女性20例）51个病变（44个转移性病变，7个良性病变）经MWA治疗的病例。采用视觉模拟量表（VAS）、SF-36身体疼痛量表（SF-36 body Pain Scale）和患者整体印象变化（PGIC）从术前到随访各阶段测量疼痛强度。不良事件按照介入放射学会（SIR）分级系统进行分类。结果：手术技术成功率100%。I级和III级不良事件分别发生在8.3%（3/36）和2.8%（1/36）的转移性疾病患者中。在那些良性病变中，没有不良事件的报道。观察到疼痛明显减轻，VAS评分从基线到最后一次随访下降了74.3%[6.7±2.3（范围：0-10）至1.8±2.3（范围：0-7）]。结论：MWA是一种安全有效的治疗骨病变患者疼痛的方法。关键相关声明：本研究证实了微波消融作为骨病变治疗的潜力，提供了显著的疼痛缓解和良好的安全性。重点：微波消融（MWA）可显著降低骨病变患者的疼痛评分，并长期保持疼痛缓解。该手术在技术上取得了很高的成功，不良事件最少，表明其安全性很高。亚组分析显示，随着时间的推移，不同手术组合在减轻疼痛方面没有显著差异。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Insights into Imaging Medicine-Radiology, Nuclear Medicine and Imaging

CiteScore

7.30

自引率

4.30%

发文量

182

审稿时长

13 weeks

期刊介绍： Insights into Imaging (I³) is a peer-reviewed open access journal published under the brand SpringerOpen. All content published in the journal is freely available online to anyone, anywhere! I³ continuously updates scientific knowledge and progress in best-practice standards in radiology through the publication of original articles and state-of-the-art reviews and opinions, along with recommendations and statements from the leading radiological societies in Europe. Founded by the European Society of Radiology (ESR), I³ creates a platform for educational material, guidelines and recommendations, and a forum for topics of controversy. A balanced combination of review articles, original papers, short communications from European radiological congresses and information on society matters makes I³ an indispensable source for current information in this field. I³ is owned by the ESR, however authors retain copyright to their article according to the Creative Commons Attribution License (see Copyright and License Agreement). All articles can be read, redistributed and reused for free, as long as the author of the original work is cited properly. The open access fees (article-processing charges) for this journal are kindly sponsored by ESR for all Members. The journal went open access in 2012, which means that all articles published since then are freely available online.